Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17548085 | 0.74 | KDM4E (0.32) | KDM4EMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19861044 | 0.74 | — | — | |
| SCHEMBL16920150 | 0.74 | — | — | |
| SCHEMBL19860997 | 0.72 | — | — | |
| SCHEMBL16920130 | 0.72 | PIK3C2B (0.31) | PIK3C2B | |
| SCHEMBL16920175 | 0.72 | — | — | |
| SCHEMBL19861014 | 0.72 | PIK3C2B (0.31) | PIK3C2B | |
| SCHEMBL15808369 | 0.71 | NPC1 (0.32) | MAPT | |
| SCHEMBL19861043 | 0.71 | — | — | |
| SCHEMBL16920133 | 0.71 | PIK3C2B (0.31) | PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141906-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO. , LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
| US-20180141906-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO. , LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
| US-9890119-B2 | Indole and azaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9890119-B2 | Indole and azaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| EP-2963013-A1 | INDOLE AND AZAINDOLE DERIVATIVES EACH HAVING AMPK-ACTIVATING ACTIVITY | Shionogi & Co., Ltd. (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-20150203450-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150203450-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203450-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAA1, PRKAA2, PRKAB1 | PIK3C2B 343/4885KDM4E 431/4885ALDH1A1 3890/4885 |
| US-20180141906-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAA1, PRKAA2, PRKAG3 | PIK3C2B 709/4885KDM4E 893/4885ALDH1A1 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.